A Phase 2 Study to Evaluate Early Bactericidal Activity, Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of Telacebec (Q203)

Condition:   Treatment-naïve, Sputum Smear-positive Patients With Drug-sensitive Pulmonary TB Interventions:   Drug: Telacebec (Q203);   Drug: Rifafour e-275 Sponsor:   Qurient Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials